{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:41:09Z","timestamp":1765960869887,"version":"3.46.0"},"reference-count":25,"publisher":"BMJ","issue":"11","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2015,10,12]]},"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the cost-effectiveness of ranolazine when added to standard-of-care (SoC) antianginals compared with SoC alone in patients with stable coronary disease experiencing \u22653 attacks\/week.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>An economic model utilising a UK health system perspective, a 1-month cycle-length and a 1-year time horizon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Patients with stable coronary disease experiencing \u22653 attacks\/week starting in 1 of 4 angina frequency health states based on Seattle Angina Questionnaire Angina Frequency (SAQAF) scores (100=no; 61\u201399=monthly; 31\u201360=weekly; 0\u201330=daily angina).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention<\/jats:title>\n                    <jats:p>Ranolazine added to SoC or SoC alone. Patients were allowed to transition between SAQAF states (first cycle only) or death (any cycle) based on probabilities derived from the randomised, controlled Efficacy of Ranolazine in Chronic Angina trial and other studies. Patients not responding to ranolazine in month 1 (not improving \u22651 SAQAF health state) discontinued ranolazine and were assumed to behave like SoC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcomes measures<\/jats:title>\n                    <jats:p>Costs (\u00a32014) and quality-adjusted life-years (QALYs) for patients receiving and not receiving ranolazine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ranolazine patients lived a mean of 0.701 QALYs at a cost of \u00a35208. Those not receiving ranolazine lived 0.662 QALYs at a cost of \u00a35318. The addition of ranolazine to SoC was therefore a dominant economic strategy. The incremental cost-effectiveness ratio was sensitive to ranolazine cost; exceeding \u00a320\u2005000\/QALY when ranolazine's cost was &gt;\u00a3203\/month. Ranolazine remained a dominant strategy when indirect costs were included and mortality rates were assumed to increase with worsening severity of SAQAF health states. Monte Carlo simulation found ranolazine to be a dominant strategy in \u223c71% of 10\u2005000 iterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Although UK-specific data on ranolazine's efficacy and safety are lacking, our analysis suggest ranolazine added to SoC in patients with weekly or daily angina is likely cost-effective from a UK health system perspective.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-008861","type":"journal-article","created":{"date-parts":[[2015,11,6]],"date-time":"2015-11-06T21:04:18Z","timestamp":1446843858000},"page":"e008861","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Ranolazine for the treatment of chronic stable angina: a cost-effectiveness analysis from the UK perspective"],"prefix":"10.1136","volume":"5","author":[{"given":"Craig I","family":"Coleman","sequence":"first","affiliation":[{"name":"University of Connecticut, School of Pharmacy and Evidence-Based Practice Center, Storrs, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Freemantle","sequence":"additional","affiliation":[{"name":"University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine G","family":"Kohn","sequence":"additional","affiliation":[{"name":"University of Saint Joseph, School of Pharmacy, Hartford, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2015,11,6]]},"reference":[{"key":"2025120618551719000_5.11.e008861.1","unstructured":"British Heart Foundation. Coronary heart disease statistics 2010. https:\/\/www.bhf.org.uk\/~\/media\/files\/research\/heart-statistics\/hs2010_coronary_heart _disease_statistics.pdf (accessed 6 Mar 2015)."},{"key":"2025120618551719000_5.11.e008861.2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-54"},{"key":"2025120618551719000_5.11.e008861.3","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-96"},{"key":"2025120618551719000_5.11.e008861.4","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000020688.24874.90"},{"key":"2025120618551719000_5.11.e008861.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.829523"},{"key":"2025120618551719000_5.11.e008861.6","first-page":"759","article-title":"Cost of illness for chronic stable angina patients enrolled in a self-management education trial","volume":"24","author":"McGillion","year":"2008","journal-title":"Can J Cardiol"},{"key":"2025120618551719000_5.11.e008861.7","doi-asserted-by":"publisher","DOI":"10.1136\/heart.89.8.848"},{"key":"2025120618551719000_5.11.e008861.8","unstructured":"National Institute for Health and Care Excellence (NICE) Pathway. Managing stable angina. http:\/\/pathways.nice.org.uk\/pathways\/stable-angina#path=view%3A\/pathways\/stable-angina\/managing-stable-angina.xml&content=view-node%3Anodes-anti-anginal-drug-treatment (accessed 19 Aug 2015)."},{"key":"2025120618551719000_5.11.e008861.9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.3.309"},{"key":"2025120618551719000_5.11.e008861.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.05.044"},{"key":"2025120618551719000_5.11.e008861.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.011"},{"key":"2025120618551719000_5.11.e008861.12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1049"},{"key":"2025120618551719000_5.11.e008861.13","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(94)00397-9"},{"key":"2025120618551719000_5.11.e008861.14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.940502"},{"key":"2025120618551719000_5.11.e008861.15","unstructured":"The National Institute for Health and Clinical Excellence Decision Support Unit. Technical support document 10: The use of mapping methods to estimate health state utility values. http:\/\/www.nicedsu.org.uk\/TSD%2010%20mapping %20FINAL.pdf (accessed 6 Mar 2015)."},{"key":"2025120618551719000_5.11.e008861.16","unstructured":"MedicinesComplete, British National Formulary. https:\/\/www.medicinescomplete.com\/about\/subscribe.htm (accessed 6 Mar 2015)."},{"key":"2025120618551719000_5.11.e008861.17","unstructured":"Consumer Price Indexes (CPI). US Bureau of Labor Statistics, Division of Consumer Prices and Price Indexes. http:\/\/www.bls.gov\/cpi\/ (accessed 2 Jun 2013)."},{"key":"2025120618551719000_5.11.e008861.18","unstructured":"National Institute for Health and Care Excellence. Donepezil, rivastigmine, galantamine and memantine for the treatment of Alzheimer's disease (including a review of TA19). http:\/\/guidance.nice.org.uk\/?action=byID&o=11599 (accessed 2 Jun 2013)."},{"key":"2025120618551719000_5.11.e008861.19","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1586\/erp.12.40","article-title":"Sativex\u00ae in multiple sclerosis spasticity: a cost-effectiveness model","volume":"12","author":"Slof","year":"2012","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2025120618551719000_5.11.e008861.20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s10198-013-0534-8","article-title":"Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain","volume":"15","author":"Hidalgo-Vega","year":"2014","journal-title":"Eur J Health Econ"},{"key":"2025120618551719000_5.11.e008861.21","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF03320519","article-title":"Una valutazione economic de ranolazina add-on nel trattamento dell'angina stabile cronica","volume":"11","author":"Lucioni","year":"2009","journal-title":"PharmacoEcono Ital Res Artic"},{"key":"2025120618551719000_5.11.e008861.22","doi-asserted-by":"crossref","first-page":"A487","DOI":"10.1016\/j.jval.2014.08.1429","article-title":"Cost-effectiveness of ranolazine for the treatment of angina pectoris in Russia","volume":"17","author":"Gorokhova","year":"2014","journal-title":"Value Health"},{"key":"2025120618551719000_5.11.e008861.23","unstructured":"European Medicines Agency. Ranexa: European public assessment report product information: Annex I\u2014Summary of product characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000805\/WC500045937.pdf (accessed 2 Apr 2015)."},{"key":"2025120618551719000_5.11.e008861.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2006.10.067"},{"key":"2025120618551719000_5.11.e008861.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.108.798009"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-008861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,7]],"date-time":"2025-12-07T02:55:22Z","timestamp":1765076122000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-008861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":25,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,6]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1136\/bmjopen-2015-008861"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-008861","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2015,11]]}}}